Vanguard Fiduciary Trust
IBRX icon

Vanguard Fiduciary Trust’s ImmunityBio IBRX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Buy
2,412,338
+289,210
+14% +$2.19M ﹤0.01% 1392
2026
Q1 		$16.3M Buy
+2,123,128
New +$14.5M ﹤0.01% 1451

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust's IBRX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its ImmunityBio (IBRX) stake by 14% in Q2 2026, buying an estimated $2.19M and bringing the position to 2,412,338 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1392.

Vanguard Fiduciary Trust first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Vanguard Fiduciary Trust held 2,412,338 shares of ImmunityBio worth $21.1M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 289,210 ImmunityBio shares in Q2 2026, an estimated $2.19M.
  • ImmunityBio made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1392 holding.
  • Vanguard Fiduciary Trust first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.